Completed Access to Information Requests

Transitional Period

Federal departments are moving their web content to Canada.ca. As a part of that process, proactive disclosure reports will become available through the Open Government portal.  During this transition, if a proactive disclosure report from a specific department is not yet available on the Open Government portal please refer to Proactive disclosure by department or agency where a copy can be found.  For any questions on this issue, please contact us at open-ouvert@tbs-sct.gc.ca .

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests previously made to the Government of Canada. If you find a summary of interest, you can request a copy of the records at no cost. For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator.

Enter keywords (e.g. institution, topic, field of interest, etc.)
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Found 32498 record(s)

Req # A-2014-00187

Adverse Reaction Report (AER) for Biaxin (clarithromycin). Report numbers: E2B_00090534, 000608315, 000605560, 000605470.

Organization: Health Canada

66 page(s)
January 2017

Req # A-2014-00315

Records containing info/stats to compare gains of applicants in the USA versus Canada by individuals having suffered from flu vaccines provided during H1N1 pandomia relating to the GBS (Guillain Barre Syndrome) such as PSURs, ADRs, Leaflets drafts and finals as well as all records regarding batch number AFLL A578BA for the 2010 flu vaccine and the batch #'s for all injured after vaccine available in any form from government bodies and the manufacturer GSK. Time frame: January 1, 2009 to December 31, 2011.

Organization: Health Canada

356 page(s)
January 2017

Req # A-2015-00064

All drafts of the following Health Canada news release re: antimicrobial resistance. Also, all comments made on the drafts prior to the release being finalized.

Organization: Health Canada

76 page(s)
January 2017

Req # A-2015-00191

Adverse Reaction Report (AER) for Kaletra (ritonavir). Report numbers: 000651588, 000651594, E2B_00224587, E2B_00227101, E2B_00232124.

Organization: Health Canada

64 page(s)
January 2017

Req # A-2015-00200

Adverse Reaction Report (AER) for Eloxatin (oxaliplatin). Report numbers: 000627904, E2B_00182325, E2B_00182378, E2B_00182421, E2B_00182427, E2B_00183016, E2B_00183078, E2B_00183138, E2B_00183284, E2B_00183299, E2B_00183897, E2B_00184011, E2B_00184227, E2B_00184718, E2B_00184852, E2B_00188792, E2B_00188833, E2B_00188849, E2B_00191217, E2B_00191846, E2B_00192471, E2B_00193447, E2B_00193449, E2B_00193771, E2B_00200452.

Organization: Health Canada

199 page(s)
January 2017

Req # A-2015-00202

All source documentation related to two Health Canada Vigibase cases: Adverse Reaction Reports (AER): 000444143, 000631655.

Organization: Health Canada

15 page(s)
January 2017

Req # A-2015-00250

Copy of the complaints submitted and compliance letters sent by Health Canada for: 1. Company: Skin Beautiful, complaint date: 2014-11-24, Product: Botox Cosmetic. 2. Company: Zwell Canada, complaint date: 2014-12-11, Product: Zwell Menomendz. 3. Organization: Canadian Generic Pharmaceutical Association, complaint date: 2014-12-11, Product: Generic Medicines. 4. Company: Pure North S'Energy Foundation, complaint date: 2015-01-09, Product: Vitamin C 100 mg. 5. Company: OrthoCanada Medical, complaint date: 2015-03-16, Product : Laser BTL High Intensity.

Organization: Health Canada

74 page(s)
January 2017

Req # A-2015-00255

Copies of original submission forms used in reporting the following Adverse Reaction Reports (AER) to Marketed Health Products Directorate (MHPD): 649358, 649363, 649364, 654087, 654102, 654107, 654570, E2B_00319718, E2B_00348689, E2B_00348619, 656797, E2B_00297285, E2B_00362023, 654998.

Organization: Health Canada

101 page(s)
January 2017

Req # A-2015-00283

Adverse Reaction Report (AER) for Humira (adalimumab). Report numbers: E2B_00315825, E2B_00315829, E2B_00315858, E2B_00391486, E2B_00369813, E2B_00371477, E2B_00345294, E2B_00364694.

Organization: Health Canada

147 page(s)
January 2017

Req # A-2015-00291

Adverse Reaction Report (AER) for Humira (adalimumab). Report numbers: 000658941, 000654142, 000655630, E2B_00389605, E2B_00339092, E2B_00315851.

Organization: Health Canada

94 page(s)
January 2017